Clin Exp Otorhinolaryngol.  2021 Aug;14(3):245-246. 10.21053/ceo.2021.01249.

Considerations for the Use of Biologic Agents in Patients With Chronic Rhinosinusitis With Nasal Polyposis

• Kim DH
• Kim SW

• KMID: 2519176
• DOI: http://doi.org/10.21053/ceo.2021.01249

Reference

1. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017; Mar. 127(3):550–5.

2. Franzese CB. The role of biologics in the treatment of nasal polyps. Immunol Allergy Clin North Am. 2020; May. 40(2):295–302.

3. Kim DW. Can neutrophils be a cellular biomarker in Asian chronic rhinosinusitis? Clin Exp Otorhinolaryngol. 2019; Nov. 12(4):325–6.

4. Wang H, Pan L, Liu Z. Neutrophils as a protagonist and target in chronic rhinosinusitis. Clin Exp Otorhinolaryngol. 2019; Nov. 12(4):337–47.

5. Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016; Nov. 138(5):1344–53.

6. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020; Feb. 58(Suppl S29):1–464.

7. Cardell LO, Stjarne P, Jonstam K, Bachert C. Endotypes of chronic rhinosinusitis: impact on management. J Allergy Clin Immunol. 2020; Mar. 145(3):752–6.

8. Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018; Jan. 54:303–10.

9. Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019; Jul. 81(1):143–51.

10. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019; Nov. 394(10209):1638–50.